At ITAAN PHARMA, innovation never rests. Every day, our development scientists are dedicated to advancing and refining our generic injectable pipeline, setting new standards for the quality and accessibility of essential therapies. With a science-driven approach and cutting-edge technology, we build a robust portfolio to meet critical patient needs while ensuring seamless regulatory approvals and commercial scalability.

Our comprehensive and integrated development services - spanning formulation, analytical, process, and regulatory expertise - are meticulously designed to meet the unique demands of injectable development. From initial material characterization and feasibility studies to formulation development, analytical development, process development, technology transfer, and stability studies, we provide end-to-end solutions for innovators and generics.

Driven by Quality by Design (QbD) principles, we harness data-driven strategies to develop and optimize parenteral dosage forms. Our dedicated R&D team fosters focused innovation and accelerates product development to deliver the best patient outcomes.

ITAAN PHARMA R&D Verticals:

• Formulation Development: Our formulation development team works on niche opportunities and NDA/ANDA formulations, utilizing a QbD approach.
• Analytical Development: We employ a science-based approach for AQbD-based method development to ensure compliance with global standards. 
• Process Development: Our process development and MSAT teams focus on identifying and addressing the impact of CPPs, ensuring scalable, high-quality production. 
• Regulatory Affairs: Our regulatory team helps define regulatory strategy, secure approvals, and support post-approval lifecycle change management.

We specialize in a wide range of formulations, including:

• Liquid Injection
• Suspension
• Microemulsion
• Depot Formulation
• Lyophilized Formulation
• Powder for Injection

Key R&D Instruments and Equipment include ICP-MS, LC-MS, GC-MS/HS, HPLCs, Lyophilizers, and Autoclaves.